SanBio and Sumitomo Dainippon Pharma Terminate Joint Development and License Agreement for SB623 in North America
Shots:
- The two companies will discontinue the joint development of SB623 for chronic stroke in North America under the termination of the agreement signed in 2010. Sumitomo will return the rights of SB623 to SanBio without any development cooperation fees or monetary remittance at milestones
- The termination follows the failure of the P-I/IIa study as it did not meet its 1EPs. Additionally- Sumitomo has no plans to sell the holding shares of SanBio
- SanBio will continue the global development of regenerative cell medicine SB623 for chronic strokes
Click here to read full press release/ article | Ref: Sumitomo Dainippon Pharma | Image: Quick Company
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com